Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Black Diamond Therapeutics, Inc.

Market Cap 98.56M 84.95M 78.18M 73.34M 138M 9.31B 139M 924M 361M 4.56B 370M 362M 15.78B P/E Ratio 2026 *
-2.66x
P/E Ratio 2027 * -1.71x
Enterprise Value 98.56M 84.95M 78.18M 73.34M 138M 9.31B 139M 924M 361M 4.56B 370M 362M 15.78B EV / Sales 2026 *
17.7x
EV / Sales 2027 * -
Free-Float
99.38%
Yield 2026 *
-
Yield 2027 * -
1 day+0.29%
1 week-9.21%
Current month-22.30%
1 month-33.14%
3 months-21.23%
6 months-34.16%
Current year-29.01%
1 week 1.66
Extreme 1.66
1.93
1 month 1.66
Extreme 1.66
3.97
Current year 1.66
Extreme 1.66
3.97
1 year 1.66
Extreme 1.66
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
13.06
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 51 10/08/2021
Chief Executive Officer 62 15/09/2023
Director of Finance/CFO 41 06/10/2024
Director TitleAgeSince
Director/Board Member 61 28/02/2017
Director/Board Member 47 30/11/2019
Director/Board Member 49 30/11/2018
Date Insider Type Main position Quantity % Market Cap.
03-19Free

Director

6,919 0.0121%
03-19
NEA Management Co. LLC
OtherCompany 0 0%
03-19Free

Director

6,105 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%-9.21%-27.82%-13.75% 98.56M
-0.71%-0.29%+56.45%+107.18% 54.92B
-1.22%+2.25%+43.78%+38.45% 44.31B
+0.09%+4.51%-14.98%-19.68% 22.96B
-3.04%-4.58%-6.97%+372.52% 21.12B
-2.91%-1.18%+7.21%-36.53% 16.31B
-2.38%-3.38%+5.53%-41.88% 15.19B
-0.63%-1.15%+25.46%+174.38% 13.32B
+1.48%+11.36%+22.59% - 12.48B
+4.10%+7.02%+104.41%+226.33% 11.21B
Average -0.50%+1.70%+21.57%+89.67% 21.19B
Weighted average by Cap. -0.87%+2.00%+30.86%+93.43%

Financials

2026 *2027 *
Net sales 5.56M 4.79M 4.41M 4.13M 7.77M 525M 7.84M 52.1M 20.35M 257M 20.85M 20.41M 890M -
Net income -40.47M -34.88M -32.1M -30.12M -56.57M -3.83B -57.14M -380M -148M -1.87B -152M -149M -6.48B -70.04M -60.37M -55.56M -52.12M -97.91M -6.62B -98.89M -657M -257M -3.24B -263M -257M -11.22B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
16/06/26 1.725 $ +0.29% 886,470
15/06/26 1.720 $ -1.71% 2,206,178
12/06/26 1.750 $ -3.85% 2,312,876
11/06/26 1.820 $ -1.62% 1,446,066
10/06/26 1.850 $ -2.63% 1,549,705
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.720USD
Average target price
9.857USD
Spread / Average Target
+473.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!